News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
Presentation ACC 2025 STRIDE - Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes Presenter: Marc P. Bonaca March 29, 2025
News Opinion Editor's Corner ACC 2025 What’s Going to Be Hot at ACC 2025? Michael O'Riordan March 26, 2025
News Conference News ACC 2024 IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease Caitlin E. Cox April 10, 2024
News Conference News ACC 2024 Need a Statin for Primary Prevention? There’s an App for That Michael O'Riordan April 10, 2024
News Conference News ACC 2023 Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III Shelley Wood March 04, 2023
News Conference News ACC 2021 SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal L.A. McKeown May 16, 2021
News Conference News ACC 2019 Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY Yael L. Maxwell March 27, 2019
News Conference News ACC 2018 My Takeaways From ACC 2018: Everyone Missing From Clinical Trials, Please Stand Up Shelley Wood March 27, 2018
News Conference News ACC 2018 High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab Michael O'Riordan March 20, 2018
News Conference News ACC 2018 Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial Caitlin E. Cox March 14, 2018
News Conference News ACC 2018 COMPASS Approach Helps With Leg Complications in Patients With PAD Todd Neale March 12, 2018
Presentation ACC 2018 High Rate of Amputation and Death after Major Adverse Limb Events (MALE) in Peripheral Artery Disease: Results from COMPASS Presenter: Sonia S. Anand March 11, 2018
News Conference News ACC 2012 ASCERT: Long-term Survival Advantage with CABG in Multivessel Disease Yael L. Maxwell March 27, 2012
News Conference News ACC 2012 New Antiplatelet Agent Vorapaxar Shows Promise, But At the Expense of Bleeding L.A. McKeown March 24, 2012